Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News
I'm LongbridgeAI, I can summarize articles.Senti Biosciences Holdings has announced a positive outcome from its FDA RMAT meeting regarding the registrational clinical and CMC strategy for SENTI-202, aimed at treating relapsed/refractory AML. The company also provided significant updates on the efficacy and durability of the SENTI-202 clinical program.
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News